Will taking Febuxostat cause kidney failure?

Long-term use of Febuxostat (Febuxostat) may increase a patient's risk of developing kidney function problems but does not necessarily directly lead to kidney failure. Febuxostat is a drug used to treat hyperuricemia and gout by lowering uric acid levels to prevent and reduce gout attacks and their associated symptoms. However, this drug may affect kidney function in some cases.

Although febuxostat may cause abnormal kidney function in some patients, not everyone will experience this. For patients taking febuxostat for a long time, the following points need special attention:

1. Regular monitoring: During the period of using febuxostat, doctors usually recommend that patients undergo regular renal function tests to ensure that the drug is not causing damage to the kidneys. These tests may include testing of serum creatinine and urinalysis.

2. Adjust dosage: For patients with renal function problems, doctors may adjust the dosage of febuxostat based on renal function to reduce the burden on the kidneys.

3. Consider the risks: Doctors will weigh the potential benefits and risks of the drug when deciding whether to use febuxostat in patients who are at risk for kidney disease or impaired kidney function.

4. Patient education: Patients should understand the possible effects of the drug, maintain communication with their doctors, and promptly report any symptoms related to kidney function, such as reduced urine output, abnormal urine, etc.

While febuxostat may increase the risk of kidney function problems, this does not mean that all users will face this problem. Everyone's physical condition is different and their reactions will be different. When deciding whether to use febuxostat and how to use it, patients should make decisions based on their individual circumstances and with the advice and guidance of their physician. For patients who have any concerns, it is crucial to fully communicate with their doctor. Doctors can conduct a comprehensive assessment based on the patient's condition and provide corresponding advice and guidance.

Febuxostat has been launched in China and has been included in medical insurance. Patients can purchase it domestically.